EUCTR2015-004263-36-GB进行中（未招募）1 期
A Phase IIa, randomised, double blind, placebo controlled, three way crossover study to assess the pharmacokinetics of RPL554 administered to adult patients with Cystic Fibrosis. - To assess the effects of inhaled RPL554 in adults with cystic fibrosis
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Sign an informed consent document indicating they understand the purpose of and procedures required for the study and are willing to participate in the study.
- •2. Male or female aged =18 years at the time of informed consent. Females of childbearing potential must have been using a consistent and reliable form of contraception (see protocol appendix 1) from the last menses before the first study treatment administration, and must commit to continue to do so during the study and for 3 months after the last dose of study treatment.
- •3. Have a 12-lead ECG recording at screening (Visit 1) and Visit 2 pre-dose showing the
- •Heart rate between 45 and 100 beats per minute
- •QT interval corrected for heart rate using Fridericia’s formula (QTcF) interval =450 msec
- •QRS interval =120 msec
- •PR interval =220 msec
- •No clinically significant abnormality including morphology (e.g. left bundle
- •branch block, atrioventricular nodal dysfunction, ST segment abnormalities)
- •4. Capable of complying with all study restrictions and procedures including ability to use the study nebuliser correctly.
- •5. Body mass index (BMI) between 18 and 30 kg/m2 (inclusive) with a minimum weight
- •6. Patients with a genetic diagnosis of CF.
- •7. Spirometry at screening demonstrating an FEV1 =40% and =80% of predicted normal.
- •8. Capable of withdrawing from long acting bronchodilators until the end of the treatment period, and short acting bronchodilators for 8 hours prior to administration of study treatment.
- •9. Clinically stable CF in the 2 weeks prior to randomisation (Visit 2).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1. History of cirrhotic liver disease or portal hypertension.
- •2. CF exacerbation requiring hospitalisation in the month prior to screening (Visit 1) or prior to randomisation (Visit 2).
- •3. Use of oral or intravenous antibiotics (in additional to usual maintenance therapy) in the 2 weeks prior to screening (Visit 1) or randomisation (Visit 2).
- •4. Other non-CF related respiratory disorders: Patients with a current diagnosis of active tuberculosis, lung cancer, sarcoidosis, sleep apnoea, known alpha-1 antitrypsin deficiency or other active pulmonary diseases.
- •5. Previous lung resection or lung transplant.
- •6. History of, or reason to believe a patient has, drug or alcohol abuse within the past 3 years.
- •7. Received an experimental drug within 3 months or five half-lives, whichever is longer.
- •8. Patients with a history of chronic uncontrolled disease including, but not limited to, cardiovascular (including arrhythmias), endocrine, active hyperthyroidism, neurological, hepatic, gastrointestinal, renal, haematological, urological, immunological or ophthalmic diseases that the Investigator believes are clinically significant.
- •9. Documented cardiovascular disease: angina, recent or suspected myocardial infarction, congestive heart failure, a history of unstable, or uncontrolled hypertension, or has been diagnosed with hypertension in last 3 months.
- •10. Has had major surgery, (requiring general anaesthesia) in the 6 weeks prior to screening (Visit 1) or will not have fully recovered from surgery, or planned surgery through the end of the study.
- •11. Infection with nontuberculous mycobacteria, methicillin-resistant Staphylococcus aureus (MRSA), or Burkholderia species.
- •12. Use of immune-suppression; long term use of prednisolone >10 mg/day.
- •13. History of malignancy of any organ system within 5 years with the exception of localised skin cancers (basal or squamous cell).
- •14. Clinically significant abnormal values for safety laboratory tests (haematology, biochemistry or urinalysis) at screening (Visit 1), as determined by the Investigator.
- •15. A disclosed history or one known to the Investigator, of significant non-compliance in previous investigational studies or with prescribed medications.
- •16. Requires oxygen therapy, even on an occasional basis.
- •17. Pregnancy or lactation (female subjects only).
- •18. Any other reason that the Investigator considers makes the patient unsuitable to participate.
研究者
相似试验
进行中（未招募）
1 期
Study to assess the effects of inhaled RPL554 in adults with cystic fibrosis.Cystic Fibrosis (CF)MedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-004263-36-DEVerona Pharma plc10
尚未招募
2 期
A study to evaluate the efficacy and safety of Desidustat oral tablets for the treatment of sickle cell diseaseCTRI/2024/06/068363Zydus Lifesciences Limited
进行中（未招募）
不适用
A randomised, double- blind, placebo controlled, cross-over efficacy and safety comparison of tiotropium 5 µg once daily and tiotropium 2.5 µg twice daily for four weeks in patients with moderate persistent asthmamoderate persistent asthmaMedDRA version: 14.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2009-018006-21-DEBoehringer Ingelheim Pharma GmbH & Co. KG90
进行中（未招募）
不适用
A Phase II, randomised, double- blind, placebo controlled, cross-overefficacy and safety comparison of tiotropium 5 µg administered oncedaily (in the evening) and tiotropium 2.5 µg administered twice dailydelivered by the Respimat® inhaler for four weeks versus placebo inpatients with moderate persistent asthmamoderate persistent asthmaMedDRA version: 12.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2009-018006-21-ATBoehringer Ingelheim RCV GmbH & CoKG90
进行中（未招募）
不适用
A Phase II, randomised, double- blind, placebo controlled, cross-overefficacy and safety comparison of tiotropium 5 µg administered oncedaily (in the evening) and tiotropium 2.5 µg administered twice dailydelivered by the Respimat® inhaler for four weeks versus placebo inpatients with moderate persistent asthmamoderate persistent asthmaMedDRA version: 12.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2009-018006-21-LVBoehringer Ingelheim RCV GmbH & CoKG90